A one-month real-world review of the Blackmagic PYXIS 12K. Image quality, RAW workflow, pros, cons, and who this full-frame camera is really for.

Pyxis Oncology released preliminary data from Phase 1 studies of MICVO for recurrent/metastatic head and neck squamous cell carcinoma.

The monotherapy trial suggested a confirmed overall-response rate of 46% and a disease-control rate of 93%. In combination with Keytruda, the confirmed overall-response rate was 71% and the ...

As of Thursday, December 18, Pyxis Oncology, Inc.’s PYXS share price has dipped by 53.39%, which has investors questioning if ...

Well, this is a nice surprise to wake up to if you’re a Blackmagic PYXIS (6K or 12K) or URSA Broadcast G2 owner. The latest ...

(ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Lara Sullivan, Pyxis Oncology CEO, joins Yahoo Finance to discuss the biotech company going public and its oncology treatments for patients with difficult-to-treat cancer. JARED BLIKRE: Well, an IPO ...

Pyxis secured S$13 million in the first close of its S$18 million growth funding round, reflecting strong investor confidence in its vessel technology, commercial traction, and regional growth ...

The round is backed by Shift4Good, Motion Ventures, SG Growth Capital & Mol Plus Proceeds will be channelled towards scaling ...

Welcome to Indie App Spotlight. This is a weekly 9to5Mac series where we showcase the latest apps in the indie app world. If you’re a developer and would like your app featured, get in contact. Pyxis ...